A detailed report covering all of Minnesota's neuromodulation capabilities (2015)

1. ®
Leading the conversation.
Minnesota Capability Brief:
NEUROMODULATION

2. 1
The Market for Neurotechnology: 2014-2018. NeuroTechReport.com (March 2014)
2
Global Neurostimulation/Neuromodulation Market. MicroMarketMonitor (Feb. 2015)
3
Evaluate MedTech Report (Oct. 2014)
4
NSF & NIH reports (Jan. 2015)
5
LifeScience Alley, Minnesota Life Science Investment Activity: 2014 Annual Report
6
https://apps.deed.state.mn.us/lmi/qcew/ResultsDisp.aspx (NAICS 334510)
7
https://apps.deed.state.mn.us/lmi/qcew/ResultsDisp.aspx
8
LifeScience Alley, Alley Insights (April 2015)
Executive Summary
Three Minnesota companies were awarded their first
Premarket Approval (PMA) or Humanitarian Device
Exemption (HDE) approval from FDA for neuromodu-
lation devices between June 2014 and January 2015.
Activity in the state spans all major target regions of
the nervous system: brain, spine, and periphery. The
Minnesota medical device ecosystem is tailored for ac-
tive implantable technology and electrotherapeutics.
Technical expertise is available for all stages of a prod-
uct’s life-cycle, including pre/clinical research, prod-
uct development, and commercialization. The Mayo
Clinic and University of Minnesota are leading research
institutions that attract world-class scientists and cli-
nicians. Both institutions invest competitively in active
programming to engage industry partnerships and pro-
mote technology commercialization. Minnesota’s early
and continued foothold in the medical device industry
provides a mature foundation, open for innovation and
entrepreneurship in neuromodulation.
Key Findings:
• 27 companies with major operations in Minnesota
– More than 40 FDA-registered neuromodulation
devices
• 42 companies providing products and services
• 25+ research and clinical centers for
neuromodulation and related expertise
• $1 billion in federal research funding and life
science investments in 20144,5
• Minnesota is ranked 1st
in U.S. for:
– Electromedical manufacturing employment6
– Medical device patents7
– PMA/510(k) awards from FDA for complex
neurological devices8
Minnesota
Neuromodulation
Capabilities
Figure 2. MN companies by type of neuromodulation device.
Figure 1. Global revenue 2013.
The global market for neuromodulation devices is strong and projected
to double by 2018, reaching $6-7 billion1,2
. Minnesota-based Medtronic
and St. Jude Medical account for 72% of worldwide sales3
.
1

3. Market
Minnesota-based compa-
nies were the first to com-
mercialize devices for Deep
Brain Stimulation (DBS),
Spinal Cord Stimulation
(SCS), and Peripheral Nerve
Stimulation (PNS). Minne-
sota-based companies con-
tinue to hold a substantial
(72%) share of the $3.5 bil-
lion global market, which is
estimated to reach $6-7 billion by 20189,10
.
The neuromodulation market is dominated by three
medical device giants - Medtronic, Boston Scientific,
and St. Jude Medical - all of which have headquarters
or significant operations in the state of Minnesota.
Greatbatch is responsible for manufacturing critical
components contained in 95% of Active Implantable
Medical Devices (AIMD) and has multiple operations in
Minnesota. The major players have successful histories
of independently developing or acquiring technologies
for neuromodulation therapies and associated surgical
operations.
Significant industry activity is focused on:
• Expanding approved indications for existing
platforms
• Producing or acquiring de-risked
technology for new patient markets
• Developing novel delivery systems
specialized for unique anatomical targets
Devices
Neuromodulation therapies are available in
implantable, minimally invasive, and non-sur-
gical options.
Implantable devices for neuromodulation of
the brain contain a programmable stimulation
unit with an internal power supply. Electricity
is delivered via ‘depth’ electrodes placed deep
in the brain or cortical electrode arrays placed
on the brain surface. Similar technology is
used for stimulating the spine and peripheral
nerves. Implanted drug pumps that deliver
small molecules directly to the cerebrospinal
fluid also achieve targeted neuromodulation.
Minimally invasive neuromodulation is achieved by
transcutaneous or percutaneous (through the skin)
stimulation via small needle-like electrodes and is
typically restricted to the spine and superficial nerves.
Non-surgical or non-invasive devices act through
many modalities. Neuromodulation of the brain and
spine are achieved through electrical direct or alter-
nating current, ultrasound, and magnetic fields. Elec-
trical stimulation is delivered to muscles and wounds
by paddle-style electrodes placed topically and often
used to treat pain and atrophy.
Figure 3. Global neuromodulation trials by subsector. Total open
trials N=1,014. Abbreviations: Neuromuscular Electrical Stimulation
(NMES), Transcutaneous Electrical Stimulation (TENS), Deep Brain
Stimulation (DBS), Transcranial Magnetic Stimulation (TMS), Tran-
scranial Electrical Stimulation (TES).
9
Global Neurostimulation/Neuromodulation Market. MicroMarketMonitor (Feb. 2015)
10
The Market for Neurotechnology: 2014-2018. NeuroTechReport.com (March 2014)
Global Overview
“Minnesota has become a local mecca for neuromodulation
just in the entities here: Medtronic, Mayo Clinic, the University
of Minnesota. You have state money. You have university focus.
You have hiring of people with that specialty. There’s a real
density of neuromodulation here. Not only are all the industry
giants physically present here but there’s a lot of feeder medical
device companies supporting it, too.”
– Gregory Molnar, PhD, Director of Neuroscience & Discovery, Medtronic plc
Medical devices that alter brain, spine, or nerve activity for
therapeutic benefit are a fast growing segment of the healthcare
industry. Neurostimulation devices were initially developed in the
1980s, based on cardiac pacemaker-inspired prototypes.
2

4. 11
https://clinicaltrials.gov, searched Jan. 20, 2014.
12
https://clinicaltrials.gov, searched Jan. 20, 2014.
Indications
FDA approval of neuromodulation devices and indica-
tions is still somewhat limited (see Table 1), in part
due to long innovation life-cycles, clinical challenges,
and uncertainty of regulatory outcomes. These issues
are being addressed head-on by Minnesota’s Medical
Device Innovation Consortium (MDIC) and LifeScience
Alley. The last two years have seen a boom in approv-
als with new announcements occurring nearly monthly.
Neuromodulation devices are registered in over 1,000
ongoing FDA-regulated clinical trials worldwide11
.
These trials are investigating over 1,300 indications,
including metabolic disorders, inflammation, migraine,
and psychiatric disorders12
. Categories or types of indi-
cations under investigation for the three major types
of commercial platforms are listed in Table 1.
Table 1. Indications approved and under investigation for Deep Brain, Spinal Cord, and Peripheral Nerve Stimulation.
FDA Status
Deep Brain
Stimulation (DBS)
Spinal Cord
Stimulation (SCS)
Peripheral Nerve
Stimulation (PNS)
APPROVED
INDICATIONS
Parkinson’s disease,
Essential tremor, Epilepsy,
OCD
Chronic pain due to Failed
Back Syndrome, Chronic
Regional Pain Syndrome,
Peripheral neuropathy, and
Ischemic pain
Obstructive Sleep Apnea,
Central Sleep Apnea,
Hypertension, Obesity,
Incontinence,
Heart failure, Migraine
INVESTIGATIONAL
INDICATIONS (#)
133 165 120
INVESTIGATIONAL
INDICATIONS
(Categories)
Behaviors and mental
disorders
Cancers and other
neoplasms
Diseases and abnormalities
at or before birth
Ear, nose, and throat
diseases
Heart and blood diseases
Muscle, bone, and
cartilage diseases
Nervous system diseases
Nutritional and metabolic
diseases
Skin and connective tissue
diseases
Substance related
disorders
Symptoms and general
pathology
Viral diseases
Wounds and injuries
Bacterial and fungal
diseases
Behaviors and mental
disorders
Blood and lymph
conditions
Cancers and other
neoplasms
Ear, nose, and throat
diseases
Eye diseases
Heart and blood diseases
Immune system diseases
Muscle, bone, and
cartilage diseases
Nervous system diseases
Nutritional and metabolic
diseases
Skin and connective tissue
diseases
Symptoms and general
pathology
Viral diseases
Wounds and injuries
Behaviors and mental
disorders
Gland and hormone
related diseases
Heart and blood diseases
Muscle, bone, and
cartilage diseases
Nervous system diseases
Nutritional and metabolic
diseases
Substance related
disorders
Symptoms and general
pathology
Urinary tract, sexual
organs, and pregnancy
conditions
Wounds and injuries
3
“Neuromodulation is an area that still has tremendous innovation opportunities. These
innovations often occur in the clinical environment around the world. However, once you get
past the original proof-of- concept, you need an ecosystem like we have here in Minnesota to
get the product fully developed and commercialized. This is the reason why so many new
medical device companies are formed here.”
– William Murray, President & CEO, Medical Device Innovation Consortium (MDIC)

5. Medtronic plc (Minneapolis, MN – operational headquarters) holds a dominant pres-
ence in the national and global neuromodulation market. The company upholds a
reputation for developing first-in-class products and acquiring IP in areas that complement or expand existing
capabilities. Neuromodulation operations are based in Fridley, MN, and will remain there following the upcom-
ing merger with Covidien.
Boston Scientific Corporation (Marlborough, MA) maintains a significant share of the U.S.
and global market in neuromodulation. The company retains active interests in Minnesota.
There is considerable interaction and flow of talent between Boston Scientific’s Cardiac
Rhythm Management Group, located in Arden Hills, MN, and the neuromodulation division located in Valencia,
CA.
St. Jude Medical, Inc., (St. Paul, MN) is a leading producer of medical technol-
ogy for treating cardiac and neurological disorders. St. Jude Medical has a history
of developing innovative technology and successful partnerships with companies to commercialize de-risked
technology. R&D operations are focused in California and Texas, with efforts spanning cardiovascular disease,
chronic pain, and neurological diseases.
Greatbatch, Inc., (Plano, TX) is a leading developer and manufacturer of medical
device systems and critical components for the neuromodulation, orthopedics, and
cardiovascular markets. The company is known for inventing the now ubiquitous lithium-powered batteries,
first used in implantable pacemakers. Today, 95% of commercially available AIMDs are designed with Greatbatch
materials. The last year saw expanded operations in Minnesota for medical device manufacturing (Greatbatch
Medical) and internal product development (QiG Group). The 2014 acquisition of CCC Medical increased inter-
national OEM capabilities.
MAJOR PLAYERS
Device Therapy Indications (*HDE)
Vercise™ Deep Brain Stimulation Parkinson’s disease*
Precision Spectra™ Spinal Cord Stimulation Chronic pain, Orthopedic surgery
Precision™
Plus Spinal Cord Stimulation Chronic pain, Orthopedic surgery
Vessix™ Renal Denervation Hypertension*
Device Therapy Indications (*IDE/CE)
Libra™
, Brio™ Deep Brain Stimulation Movement disorders*
Prodigy™*
, Eon™
, Protégé™ Spinal Cord Stimulation Pain*
Genesis™ Optic Nerve Stimulation Chronic migraine*
Device Therapy Indications (*CE)
Algostim™
, Algovita™ Spinal Cord Stimulation Chronic pain*
Device Therapy Indications
Activa® Deep Brain Stimulation
Parkinson’s disease, Essential
tremor, Dystonia, OCD
SynchroMed®
II
Intrathecal Infusion Pump (Drug
Delivery)
Cancer pain, Chronic pain,
Severe spasticity
Enterra® Gastric Electrical Stimulation Nausea/vomiting from gastroparesis
InterStim® Sacral Neuromodulation Systems
Overactive bladder, Bowel
incontinence, Urinary retention
AdaptiveStim®
+SureScan® Spinal Cord Stimulation – MRI
compatible
Chronic pain
4

6. See Appendix 1 for directory and contact information for companies listed above and additional businesses
providing supporting goods and services.
NEUROMODULATION IN MINNESOTA
BRAIN
Boston Scientific
Functional Neuromodulation
Medtronic
Monteris Medical
St. Jude Medical
SPINAL CORD
Boston Scientific
Greatbatch Medical
Mainstay Medical
Medtronic
St. Jude Medical
NERVES
Advanced Bionics
BioControl Medical
Boston Scientific
Cardionomic
Chattanooga Group
Cogentix Medical
(Uroplasty)
CVRx
Empi
Enopace Biomedical
EnteroMedics
Envoy Medical
Holaira
Inspire Medical Systems
Medi-Stim
Medtronic
Novum Therapeutics
Respicardia
SPR Therapeutics
St. Jude Medical
Uni-Patch
WR Medical Electronics
Figure 4. MN companies by anatomical target.
5

7. Minnesota supports a thriv-
ing and diverse ecosystem for
neuromodulation enterprise.
There are 27 companies with
headquarters or significant op-
erations in Minnesota respon-
sible for producing at least 40
stimulation systems across all
platform areas (Figure 2 and
Figure 3). Another 40 compa-
nies work in the surrounding
space, offering contract-based
expertise in intellectual prop-
erty (IP), design, engineering,
surgery, quality, regulatory, fi-
nance, manufacturing, patient
data, and clinical testing. Min-
nesota established itself early
as a source of neurological ex-
pertise and continues to show
rapid growth of new industry
development (Figure 5).
Funding for the life sciences is
on the rise and holding firm. In 2014, the state at-
tracted over $1 billion for research and enterprise in
the life sciences. More than 1,000 federal research
grants worth $740.6 million were awarded, up 5.2%
from 201313,14
. 2014 also saw a six-year high of $430
million invested in life science businesses, with $320
million (74%) going to medical device companies15
.
Minnesota’s
global po-
sitioning in
the neuro-
modulation
industry is
well-estab-
lished. Having grown on the shoulders of the cardiac
pacemaker industry, neuromodulation has deep roots
in Minnesota and a wide reach. Greg Molnar, PhD, Di-
rector of Medtronic’s Neuroscience Discovery Division,
commented that “You naturally have new geographies
with pre-existing people and efforts. [It] makes sense
to leave it there and leverage the global nature. Still,
Medtronic’s R&D headquarters for neuromodulation
are in Minnesota. The convergence of all that infor-
mation and activity comes together to business and
decisions based here in Minneapolis.” Gregory Molnar,
PhD, Director of Neuroscience & Discovery, Medtronic
plc emphasized that the announcement to retain neu-
romodulation operations in Minnesota following the
Covidien merger, the largest in medical device history,
is a clear indicator of the value of having such a criti-
cal mass of industry activity in Minnesota.
Regional activity in neuromodulation is strong across
the spectrum, from pre-clinical and basic research
to startups and established corporations. The Twin
Cities are known for excellence in engineering and
medicine, consistently outranking other metro areas
in medical device patents and inventive patents16
. To
promote early stage ventures in healthcare and medi-
cal technology, a variety of startup incubator spaces
and accelerators complement community- and mem-
ber-based programs geared toward education and
network expansion for entrepreneurs working with
biomedical technology. In addition to the major play-
ers and supporting industry, the University of Minne-
sota and Mayo Clinic fund clinical research programs,
hire world class scientists, and provide unparalleled
facilities. Both employ locally-sourced personnel with
years of success in the medical device industry to pro-
vide structured systems for IP development, commer-
cialization, and licensing.
Figure 5. Growth of neurosurgery and neuromodulation in MN.
Source (2014) Millions
Life Science Investments $430
NIH Awards $446
NSF Awards $155
TOTAL $1,031
13
http://www.startribune.com/local/minneapolis/288484351.html?page=1&c=y
14
http://projectreporter.nih.gov/reporter.cfm; http://www.nsf.gov/awardsearch/
15
LifeScience Alley, Minnesota Life Science Investment Activity: 2014 Annual Report
16
mn.gov/deed, Compare MN and metropolitan areas
“Minnesota is a Disneyland
for medical devices.”
– John Linehan, PhD, Clinical Professor of Biomedical
Engineering, Northwestern University
6

8. Deep Brain Stimulation (DBS)
Medtronic’s Activa®
system is the leading device op-
tion for treating Parkinson’s disease and essential
tremor (Humanitarian Device Exempt status for dys-
tonia and Obsessive Compulsive Disorder). Boston Sci-
entific is the other leading provider of a DBS system,
with Vercise™, approved for successful treatment of
Parkinson’s disease. While St. Jude Medical awaits
FDA approval of their DBS systems - Libra™, Libra XP™,
and Brio™ - they are approved for treatment of Par-
kinson’s and dystonia in Europe and Australia. Early
success in treating Parkinson’s is promising. However,
one entrepreneur with decades of experience in neu-
romodulation noted that the Parkinson’s market is
reaching saturation and faces significant competition
from pharmaceutical treatment options. In light of the
aging population, neurodegenerative disorders are of
significant interest. Functional Neuromodulation is
using Medtronic’s DBS platform in Phase I/II clinical
trials for early stage Alzheimer’s disease. Multiple un-
successful attempts at using DBS to treat depression
attest to the substantial efforts being made to break
into new disease applications and address significant
unmet clinical needs.
Spinal Cord Stimulation (SCS)
Medtronic, St. Jude Medical, and Boston Scientific
all produce FDA approved SCS devices to treat
chronic pain. Medtronic’s AdaptiveStim® and
SureScan® systems offer a distinct capability of
MRI compatibility. Boston Scientific’s Precision™
Plus system recently took over a majority of
the SCS market by offering 16 electrodes, twice
the number of stimulation contacts as any other
commercially available product. St. Jude Medical
recently received FDA approval for its Protégé™
implantable pulse generator, the first fully
upgradeable neurostimulator system. Greatbatch,
well-known for producing electromedical compo-
nents, expects U.S. approval of their first fully-
functioning stimulation platform, Algovita™, in
mid-2015. Greatbatch’s neuromodulation product
development is performed by its subsidiary, the
QiG Group, located in Blaine, MN. Greatbatch’s
neuromodulation exper-tise is built primarily upon
mergers with two Minnesota neuromodulation bus-
inesses, Enpath and Quan Emerteq, in 2007.
Although headquarters relocated from New York to
Texas in 2012, ties to the Twin Cities remain strong.
Peripheral Nerve Stimulation (PNS)
Peripheral nerves are attractive targets for neuromod-
ulation-based therapies due to relatively easy surgical
access and an established historical body of medical
knowledge. Medtronic was quick to commercialize de-
vices in this area and recently expanded its portfolio
with the early 2015 acquisition of Uro-Solutions’ per-
cutaneous nerve stimulator to treat overactive blad-
der. Four mid-sized companies headquartered in the
Twin Cities (listed below) are approved to commer-
cially market peripheral nerve stimulation devices in
the U.S. Three of these companies received FDA ap-
proval between June 2014 and January 2015.
Cogentix Medical Inc., (Uroplasty) produces the Ur-
gent®
PC Neuromodulation System for sacral nerve
stimulation to treat overactive bladder. PMA status
was awarded in 2005. Present efforts are focused on
improving reimbursement.
CVRx developed and produces Barostim neo™, a first-
in-class MRI-compatible, implantable device for re-
storing cardiac and vascular function via the sympa-
thetic nervous system. HDE status was awarded for
hypertension in December 2014 and FDA approval for
heart failure is anticipated.
EnteroMedics, Inc.’s vBloc®
Therapy, delivered
through the Maestro® System, pioneered vagal-nerve
stimulation for weight loss and is exploring efficacy in
related metabolic disorders. PMA status was granted
by FDA in January 2015, contingent upon a 5-year,
Phase IV follow-up study.
Inspire Medical Systems, Inc., spun out of Medtronic
to produce the Inspire® Upper Airway Stimulation de-
vice for stimulating the hypoglossal nerve to treat Ob-
structive Sleep Apnea. FDA awarded
PMA status in April 2014.
MINNESOTA - IMPLANTABLE &
MINIMALLY INVASIVE SYSTEMS
7

9. 17
mn.gov/deed, Compare MN and metropolitan areas
18
https://apps.deed.state.mn.us/lmi/qcew/ResultsDisp.aspx (NAICS 334510)
19
https://apps.deed.state.mn.us/lmi/qcew/ResultsDisp.aspx (NAICS 334510)
Non-surgical Neuromodulation
Methods that achieve neuromodulation via non-inva-
sive or non-surgical means are the subject of more
than half (61%) of all FDA trials currently open world-
wide. Significantly more trials are targeting the brain
(38%) than peripheral nerves (23%). While under ac-
tive clinical investigation, non-surgical neuromodula-
tion devices represent a much smaller portion of the
commercial market.
Transcranial Magnetic and Ultrasound Stimulation
The University of Minnesota’s MINCEP Epilepsy Care
Center and Brain Plasticity Laboratory are leading
Minnesota’s efforts in therapeutic Transcranial Mag-
netic Stimulation (TMS) and Functional Ultrasound
Stimulation. Major research efforts are directed to-
ward stroke recovery and dystonia. Clinicians are
also exploring applications in treatment-resistant
depression and rehabilitation following brain-related
trauma. The center recently expanded due to notable
funding awards from MnDRIVE and NIH.
Neuromuscular Electrical Stimulation and Transcu-
taneous Electrical Nerve Stimulation (NMES/TENS)
DJO Global is the largest non-surgical orthopedic re-
habilitation device producer in the U.S. Two signifi-
cant acquisitions include Minnesota-based companies,
EMPI and Chattanooga Group, with the latter main-
taining operations in the state. Minnesota’s Medi-
Stim, also produces full electrotherapy systems and
garments for portable devices.
MINNESOTA - NON-SURGICAL
STIMULATION SYSTEMS
Medical Device Manufacturing
Minnesota produced the first FDA-approved neuro-
stimulation devices and continues to be a global
leader in active implantable medical devices. The
Minneapolis-St. Paul metropolitan area is the nation’s
leader in medical device patents and manufacturing
jobs17
. Within the electrotherapeutics manufacturing
subsector, the Twin Cities metro area is home to 23%
of all U.S. employees and claims more than 25% of
total wages18
. The roughly 13,000 workers in the state
are distributed across 66 establishments, 56 of which
are located in the greater metro area19
. In addition to
manufacturing, the medical device ecosystem is flour-
ishing and supports all phases of the neuromodulation
device life-cycle.
Medical Device Development
Notable operations span medical device R&D, IP,
prototype production, sterilization, project manage-
ment, regulatory, commercialization, and finance
(see Appendix 1).
Evergreen Medical Technologies, Inc. specializes
in active implantable medical device development,
manufacturing, testing, and clinical insight. The ma-
jority of clientele (60%) is local. Known for electro-
medical engineering expertise, 90% of contract efforts
focus on neuromodulation products.
Greatbatch Medical provides a wide variety of con-
tract medical device development and manufacturing
services. The company also designs and manufactures
critical electromedical technologies to enhance the
reliability and performance of medical devices and
procedures, including batteries, device headers and
enclosures, leads, coated electrodes, and more.
Minnetronix, Inc., is a medical technology and inno-
vation company, specializing in electronic and elec-
tromechanical devices. Minnetronix provides ideas,
innovation, and strategic guidance, as well as design,
development, and manufacturing services to medical
device companies.
MINNESOTA – SUPPORTING ENTERPRISE
“Minnesota is the best place
to find people who know the
neuromodulation business
and can grow it.”
– John Swoyer, Executive Director
of Product Development, QiG Group
8

10. Clinical & Surgical Expertise
Minnesota has been the site for over 80 neuromodu-
lation clinical trials20
. Minnesota’s expertise in clini-
cal trials parallels the interests of the companies and
organizations within the area. Mayo Clinic and the
University of Minnesota established neurosurgery de-
partments early in the twentieth century, providing
an easily accessible source of expertise for developing
and testing implantable technology. See Appendix 2
for directory of clinicians and research centers.
Talent & Workforce
The population of Minnesota is highly educated and
has access to numerous specialized training programs
from certificate to doctorate. Overall, Minnesota
boasts one of the highest literacy rates in the U.S.
Education is consistently supported by the state legis-
lature and local programming. The University of Min-
nesota is ranked in the top 25 research universities in
the world by the Center for Measuring University Per-
formance. The university’s high standing is in part due
to the superior faculty and trainees affiliated with the
Medical School and College of Science & Engineering.
Healthcare
Minnesota’s thriving healthcare sector provides com-
plementary services and expertise to the neuromodu-
lation sector. UnitedHealth Group is the world’s larg-
est healthcare and insurance provider. UnitedHealth
is headquartered in Minnetonka, MN, and reports over
20 other facilities in the state. The leading healthcare
investment bank, Piper Jaffray, is headquartered in
downtown Minneapolis, offering both financial analy-
sis and investing opportunities. Multiple accelerators
and co-working spaces are available for healthcare
endeavors, both early stage and growing, including
Healthcare.mn and TreeHouse Health.
Supporting Organizations
Non-governmental organizations and state-based pro-
grams are important drivers of medical device success
in Minnesota. See Appendix 2 for additional support-
ing organizations.
MINNESOTA –
SUPPORTING INFRASTRUCTURE
LifeScience Alley spends significant efforts advo-
cating for federal and state legislation that pro-
motes a profitable business climate. These efforts
produced the Angel Tax Credit, now offering up to
$15 million in tax credits in 2015. LifeScience Alley
also provides industry intelligence, programming,
and business referral opportunities to specifically
address challenges faced in the health technology
and medical device industries.
The Medical Device Innovation Consortium (MDIC)
aims to advance regulatory science through its pub-
lic-private partnership among industry stakehold-
ers, governmental agencies, and patient/physician
groups. The MDIC is presently working with the FDA
to establish standardized safety guidelines for stim-
ulation parameters in nerve tissue.
BioAM, LLC, in Rochester, MN, is a community-
based organization promoting economic develop-
ment in life sciences through education and net-
working. BioAM works with regional organizations
like Destination Medical Center to elevate activities
in healthcare and medicine across the state.
The MN Neuromodulation Consortium was estab-
lished in January 2015 to provide a centralized ac-
cess point to the region’s extensive collection of
resources and expertise in neuromodulation.
20
https://clinicaltrials.gov, searched Jan. 20, 2014.
9

11. ‘Closed-loop’ Systems
Recent advancements in neuroscience, electrical en-
gineering, and biosensors have enabled ‘closed-loop’
systems, capable of sensing ongoing brain or nerve
activity and incorporating it into stimulation param-
eters for optimized therapeutic efficacy in real-time.
California-based Neuropace’s RNS® System is the first
to U.S. market with this technology, although many
efforts are underway to make this technology the gold
standard of care.
Pre-clinical
Powerful pre-clinical capabilities are provided by op-
togenetics and pharmacosynthetics, which make use
of genetics to achieve selective cellular and
anatomical targeting. The delivery of light and
synthetic small molecules, respectively, is used
to achieve neuromodulation. Both approaches
are making major strides at the bench but are
not used therapeutically in their present itera-
tions due to limited acceptance of gene thera-
py in humans.
Non-surgical
While challenges to commercialization remain, non-
surgical options are gaining traction. Transcranial
electrical, magnetic, and ultrasound stimulation have
demonstrated clinical efficacy but are significantly
limited by high energy demands, large device size,
and ease of use. These modalities often require daily
or weekly clinical visits to receive treatment, posing
considerable geographic limitation to patient access.
Some groups are addressing these limitations by de-
veloping small, portable devices to deliver small elec-
trical charges to ‘superficial’ nerves near the surface
of the body, e.g., via the ear canal like Novum Thera-
peutics.
Therapeutics
Medical diseases and disorders that affect the nervous
system are diverse in nature and widespread across
demographics. Finding successful treatment options is
often challenged by the complex nature of the dis-
eases and limited understanding of symptomatology
and etiology, as is the case with many psychiatric and
neurodegenerative disorders. This sets the stage for
numerous potential physiological targets, low compe-
tition in treatment-resistant diseases, and significant
drive for innovative treatments and novel technology.
Beyond classical nervous system disorders, diseases of
peripheral tissues often have a neurological compo-
nent or could benefit from neurological interventions.
Metabolic disorders, like obesity and type 2 diabetes,
are growing at epidemic proportions and present sig-
nificant patient needs. Inflammation treatments are
another area of great commercial potential. Urinary
and fecal incontinence is a major untapped market
that will soon be filled by implantable neuromodula-
tion devices that are under clinical investigation by
numerous sponsors.
Prosthetics
In amputees and trauma victims, neuromodulation
is aiding recovery following injury by promoting re-
growth of severed nerves or spinal cords. Prosthetic
limbs are being developed with biomimetic ‘skin’,
capable of sensing temperature and pressure, which
are paired with brain-computer interfaces to restore
feeling and mobility. Much of the development work
in this area is funded by the U.S. Department of De-
fense, with a focus on the veteran population.
Enhancements
Beyond medical applications, enhancement of healthy
individuals is of significant interest, particularly by the
military and private sector. These efforts are present-
ly limited to non-surgical methods and have reported
improvements in attention, anxiety, and mood. Devel-
opment of these devices is unencumbered by costly
pivotal trials. However, without FDA-backing and the
aid of reimbursement, devices must be marketed to
the private consumer and paid for out-of-pocket, sig-
nificantly limiting potential revenues.
EMERGING TECHNOLOGY
UNMET NEEDS
“LifeScience Alley is great because
they continue to build connections
and focus on issues of the day.”
– Todd Langevin, President & COO, Functional Neuromodulation
10

12. Market growth is strong for neuromodulation-based
therapies; it is predicted to double in the next four
years21,22
. In the initial years of neurostimulation tech-
nology, Thom Gunderson, Senior Financial Analyst at
Piper Jaffray, noted that “the best and brightest tal-
ent was attracted to the success and stability of the
cardiac industry, which slowed innovation in the neu-
romodulation sector.” Today, “neuromodulation is an
open market with great potential that is attractive to
investors.”
Early safety demonstrations and lasting patient suc-
cesses in treating pain and Parkinson’s disease con-
tinue to bolster physician support for SCS and DBS,
respectively. Manufacturers of FDA-approved stimula-
tion systems are able to provide entrepreneurs with
verified technology for early-phase investigations,
ultimately leading to lower cost, lower risk clinical
trials.
Minnesota is a powerful global center for neuromodu-
lation industry. Minnesota established a strong lead
in neuromodulation therapies due to early success
in cardiac stimulation. Talent and technology is eas-
ily transferred to a wide range of active implantable
medical devices. The Twin Cities metropolitan area
is home to small and large companies working in the
neuromodulation space. The historic legacy serves the
area well, providing emerging enterprises with talent,
expertise, and financing. Smaller ventures run the risk
of being overshadowed by major players but can eas-
ily take advantage of the close proximity by accessing
corporate talent on a consulting basis and leveraging
connections for favorable exit strategies.
Cheryl Matter, PhD
Vice President of Intelligence & Research, LifeScience Alley
cmatter@lifesciencealley.org
952.746.3817
Anastasia N. Zink
Research Fellow, LifeScience Alley
PhD Candidate, Graduate Program in Neuroscience, University of Minnesota
MARKET CLIMATE
SUMMARY
CONTRIBUTORS
This Capability Brief is a living document and will be updated with new information as it is discovered or
received. Please send any additional information for consideration to Cheryl Matter, PhD, Director of
Intelligence & Research, at cmatter@lifesciencealley.org or 952.746.3817.
Questions/Comments/Edits
21
Global Neurostimulation/Neuromodulation Market. MicroMarketMonitor (Feb. 2015)
22
The Market for Neurotechnology: 2014-2018. NeuroTechReport.com (March 2014)
11

13. We would like to thank all of the neuromodulation and neuroscience experts in local industry
and academia who shared their insights and thoughts during the preparation of this report.
This work would not have been possible without their assistance.
The following experts and executives were consulted during the creation of this report:
David Anderson
Senior Vice President of R&D, St. Jude Medical, Inc.
Bryce Beverlin II, PhD
Medical Devices Center Innovation Fellow, University of Minnesota
Charles Billington, MD
Professor, Department of Medicine, University of Minnesota
Dori Henderson, PhD
Program Manager, MnDRIVE Brain Conditions Initiative, University of Minnesota
Thomas Gunderson
Senior Financial Analyst, Piper Jaffray Companies
Matthew Johnson, PhD
Assistant Professor, Department of Biomedical Engineering, University of Minnesota
Robert Kieval, PhD
Executive Vice President & CTO (Founder), CVRx, Inc.
Mark Knudson, PhD
President & CEO, EnteroMedics, Inc.
Todd Langevin
President & COO, Functional Neuromodulation, Ltd.
Gregory Molnar, PhD
Director of Neuroscience & Discovery, Medtronic plc
William Murray
President & CEO, Medical Device Innovation Consortium (MDIC)
Randall Nelson
President, Evergreen Medical Technologies
Tay Netoff, PhD
Assistant Professor, Department of Biomedical Engineering, University of Minnesota
David Rhees, PhD
Executive Director, The Bakken Museum
Barry Rittberg, MD
Assistant Professor, Department of Psychiatry, University of Minnesota
John Swoyer
Executive Director of Product Development, QiG Group
David Wechter
Senior R&D Engineer, Neuromodulation, Boston Scientific Corporation
ACKNOWLEDGEMENTS
12

14. Neuromodulation Devices
Advanced Bionics
(Parent Corporation: Sanova Holding A.G.)
Hopkins, MN; Stäfa, Switzerland
www.advancedbionics.com
952.930.0686
Advanced Bionics produces a cochlear implant
for hearing loss.
BioControl Medical Ltd.
(Parent Corporation: Rainbow Medical)
Minneapolis, MN
www.biocontrol-medical.com
BioControl Medical produces the CardioFit System
for vagal nerve stimulation to treat heart failure.
Boston Scientific Corporation
Marlborough, MA; St. Paul, MN
www.bostonscientific.com
508.683.4000; 651.582.4000
Kelly Leadem
media@bsci.com
Boston Scientific develops and commercializes a
diverse neuromodulation device portfolio.
Cardionomic, Inc.
Forest Lake, MN
www.cardionomicinc.com
651.964.0170
Cardionomic is developing a device for
neuromodulating the terminal branches of the
cardiac plexus to treat acute decompensated
heart failure (ADHF).
CerebralRx Ltd.
(Parent Corporation: Rainbow Medical, spinoff of
BioControl)
Minneapolis, MN
www.biocontrol-medical.com
CerebralRx produces the FitNeS Vagus Nerve
Stimulator for refractory epilepsy and other
indications.
Chattanooga Group, Inc.
(Parent Corporation: DJO, LLC)
St. Paul, MN; Vista, CA
www.djoglobal.com/our-brands/chattanooga
Chattanooga Group is the world’s largest
manufacturer of TENS/NMES rehabilitation
equipment for treating musculoskeletal,
neurological, and soft tissue disorders.
Cogentix Medical, Inc.
(Uroplasty, Inc.)
Hopkins, MN
www.cogentixmedical.com
866.258.2182
Cogentix Medical (Uroplasty, Inc.) produces Urgent®
PC Neuromodulation System for percutaneous tibial
nerve stimulation to treat overactive bladder and
associated symptoms of urinary urgency, urinary
frequency, and urge
incontinence.
CVRx, Inc.
Minneapolis, MN
www.cvrx.com
763.416.2840
CVRx Inc. produces Barostim neo™ for barostim
receptor stimulation in the carotid artery to treat
hypertension and heart failure.
Empi, Inc.
(Parent Corporation: DJO, LLC)
St. Paul, MN; Clear Lake, SD
www.djoglobal.com/our-brands/empi
651.484.9381
Empi is a leading distributor of non-invasive
electrical stimulation (TENS/NMES) devices and
other orthopedic products used for pain
management, orthopedic rehabilitation, physical
therapy, fitness, and sport performance
enhancement.
EnteroMedics, Inc.
St. Paul, MN
www.enteromedics.com
651.634.3003
EnteroMedics produces the vBloc Maestro®
Rechargeable System for vagal nerve blocking in
the treatment of obesity.
APPENDIX 1:
Neuromodulation-Related
Businesses & Resources
13

15. Envoy Medical Corporation
St. Paul, MN
www.envoymedical.com
651.361.8000
Envoy Medical produces Esteem, a middle-ear im-
plant for moderate to severe nerve-related (sensori-
neural) hearing loss.
Functional Neuromodulation Ltd.
Minneapolis, MN
www.functionalneuromodulation.com
info@fxneuromod.com
866.296.4040
Functional Neuromodulation is developing DBS to
treat mild Alzheimer’s disease.
Greatbatch Medical
(Parent Corporation: Greatbatch, Inc.)
Plymouth, MN
www.greatbatchmedical.com
763.951.8181
Greatbatch Medical produces the Algovita™ and
Algostim™ spinal cord stimulation systems for
chronic pain; the company also designs and
manufactures critical components for complex
medical devices and procedures.
Holaira Medical, Inc.
Plymouth, MN
www.holaira.com
763.450.2800
Holaira Medical produces a device for Targeted Lung
Denervation (TLD) to reduce overactive airway nerve
activity for treatment of chronic obstructive
pulmonary disease (COPD).
Inspire Medical Systems, Inc.
Maple Grove, MN
www.inspiresleep.com
763.205.7970
Inspire Medical Systems sells Inspire®
(stimulator,
breathing sensor, stimulation lead, remote) for
Obstructive Sleep Apnea.
Mainstay Medical, Inc.
Dublin, Ireland; Plymouth, MN
www.mainstay-medical.com
Mainstay Medical produces the ReActiv8™
implantable spinal stimulation device for chronic
low back pain.
Medi-Stim, Inc.
Wabasha, MN
www.medi-stim.com
651.565.2400
Medi-Stim produces a comprehensive line of
non-invasive electrotherapy products to treat
neural and muscular pain or rehabilitative
conditions.
Medtronic plc
Dublin, Ireland; Minneapolis, MN
www.medtronic.com
763.514.4000
Justin Ihle, Program Manager, Public Relations,
Neuromodulation
justin.ihle@medtronic.com
Medtronic develops and commercializes a diverse
neuromodulation device portfolio.
Monteris Medical, Inc.
Plymouth, MN; Winnipeg, Manitoba, Canada
www.monteris.com
763.253.4710
Monteris Medical produces the NeuroBlate®
System for MRI-guided neurosurgical ablation.
Novum Therapeutics, Inc.
Minneapolis, MN
www.novumthera.com
763.360.2931
Evan Johnston, President & CEO
ejohnston@NovumThera.com
Novum Therapeutics produces Nocturne™
non-invasive neuromodulation of cranial nerve
through the ear canal for Obstructive Sleep Apnea.
Pepin Manufacturing, Inc.
Lake City, MN
www.pepinmfg.com
651.345.5655
Pepin Manufacturing provides contract-based
product design, development, and manufacturing.
The company also offers electrotherapy electrodes,
device components, TENS stimulation units, and
their accessories.
QiG Group
(Parent Corporation: Greatbatch, Inc.)
Blaine, MN
www.qiggroup.com
763.786.7400
QiG Group has broad capabilities and expertise in
neurostimulation systems, which typically include
implantable pulse generators, leads, and
programmers.
14

16. Neuromodulation Devices (Cont’d)
Respicardia, Inc.
Hopkins, MN
www.respicardia.com
952.540.4470
Respicardia produces the Remedē®
System for
phrenic nerve stimulation of the diaphragm to treat
sleep apnea.
SPR Therapeutics, LLC
(Parent corporation: NDI Medical LLC)
Minneapolis, MN
www.sprtherapeutics.com
info@fxneuromod.com
216.378.9108
Mark Stultz, Senior Vice President, Market
Development
info@sprtherapeutics.com
216.378.9106 x103
SPR Therapeutics produces Smartpatch PNS and
Micropulse PNS systems, percutaneous peripheral
nerve stimulation systems for interventional pain
management.
St. Jude Medical, Inc.
St. Paul, MN
www.sjm.com
651.756.2000
St. Jude Medical develops and commercializes a
diverse neuromodulation device portfolio.
Uni-Patch
(Parent Corporation: Covidien Ltd.)
Wabasha, MN
www.uni-patch.com
651.565.2601
Uni-Patch produces non-implantable electrodes
and garments for use with TENS, NMES, FENS,
post-operative, interferential, and galvanic
stimulation systems.
WR Medical Electronics Co.
Maplewood, MN
www.wrmed.com
651.604.8400
WR Medical Electronics Co. produces the Hilger,
Silverstein Facial Nerve Stimulators for
electrodiagnostic testing for facial paralysis.
Design, Development, &
Manufacturing - Devices &
Components
Advanced Medical Electronics Corporation
Maple Grove, MN
www.ame-corp.com
763.463.4814
Advanced Medical Electronics is a product-focused
research and development company specializing in
medical devices.
Cymbet Corporation
Elk River, MN
www.cymbet.com
763.633.1780
Cymbet Corporation specializes in rechargeable,
thin film, solid state batteries for microelectronic
systems.
Devicix, LLC
Eden Prairie, MN
www.devicix.com
952.368.0073
Devicix provides electromedical device design,
engineering, prototyping, development, regulatory/
certification, and commercialization expertise.
Donatelle Medical
New Brighton, MN
www.donatellemedical.com
651.633.4200
Donatelle Medical provides medical device
expertise in development, manufacturing, and
commercialization of cardiac rhythm management,
neuromodulation, surgery, diabetes, and spine.
Evergreen Medical Technologies, Inc.
St. Paul, MN
www.evergreenmedtech.com
651.646.7700
Randall Nelson
Evergreen Medical Technologies provides
electromedical device design, engineering,
prototyping, development, certification, and
regulatory expertise.
Greatbatch Medical
(Parent Corporation: Greatbatch, Inc.)
Minneapolis, MN
www.greatbatchmedical.com
612.676.7200
Greatbatch Medical designs and manufactures
critical technologies that enhance the reliability
and performance of medical devices and procedures.
15

17. Heraeus Medical Components, LLC
(Parent Corporation: Heraeus Holding GmbH)
St. Paul, MN
www.heraeusmedicalcomponents.com
651.792.8500
Heraeus Medical Components delivers from ingot to
complex engineered assembly.
Matrix MedTech, Inc.
Maple Grove, MN
www.matrixmedtech.com
763.331.8671
Scott Olson
Scott.Olson@matrixmedtech.com
Matrix MedTech provides research, design,
development, prototyping, and manufacturing
expertise for medical device components.
Minnetronix, Inc.
St. Paul, MN
www.minnetronix.com
651.917.4060
Jeremy Maniak, COO
jmaniak@minnetronix.com
Minnetronix specializes in medical device design,
manufacturing, and IP.
Nortech Systems Incorporated
Wayzata, MN
www.nortechsys.com
952.345.2244
Zak Tomczak, Business Development
ztomczak@nortechsys.com
612.590.7822
Nortech Systems provides electronics manufacturing
services (EMS) for the medical device industry and
others.
North American Science Associates Inc. (NAMSA)
Minneapolis, MN
www.namsa.com
763.287.3830
NAMSA is a medical research organization providing
expert regulatory, laboratory, clinical, and
compliance services to medical device
manufacturers.
Omnetics Connector Corporation
Minneapolis, MN
www.omnetics.com
763.572.0656
Omnetics Connector Corporation produces micro and
nano connectors for military, commercial, and
medical applications.
Pepin Manufacturing, Inc.
Lake City, MN
www.pepinmfg.com
651.345.5655
Pepin Manufacturing provides R&D, design, and
manufacturing expertise, and also specializes in
custom electrodes for electrotherapy products.
PMT Corporation
Chanhassen, MN
www.pmtcorp.com
952.470.0866
PMT manufactures products for neurosurgery,
orthopaedics, and plastic and reconstructive surgery.
Smiths Medical ASD Inc.
(Parent Corporation: Smiths Group plc)
St. Paul, MN
www.smiths-medical.com
OEM.Inquiries@smiths-medical.com
651.633.2556
Smiths Medical provides clinical and technical
support services for multi-national medical device
studies and global product distribution.
Stellar Technologies, Inc.
Brooklyn Park, MN
www.stellar-technologies.com
763.493.8556
Dennis Forcelle, Director of New Technologies
dforcelle@stellar-technologies.com
763.493.8556 x103
Stellar Technologies provides product development,
qualification, and component manufacturing of
medical products, specializing in
neurostimulation.
Summit Medical, Inc.
(Parent Corporation: Shore Capital Partners, LLC)
St. Paul, MN
www.summitmedicalusa.com
customerservice@summitmedicalusa.com
651.789.3939
Summit Medical offers expertise in medical device
manufacturing, regulatory, quality, engineering,
sales, and marketing.
Teren Med Inc.
Minneapolis, MN
814.571.3888
Teren Med is an electromedical equipment
manufacturer.
16

18. Design, Development &
Manufacturing - Devices &
Components (Cont’d)
Worrell Design, Inc.
Minneapolis, MN
www.worrell.com
612.638.6000
Worrell Design provides expertise in product design,
development, and strategy.
Neurosurgery Equipment
ev3 Inc.
(Parent Corporation: Covidien Ltd.)
Plymouth, MN
www.ev3.net
customerservice@ev3.net
763.398.7000
ev3 offers medical devices for neurosurgery
applications.
IMRIS Inc.
Minnetonka, MN; Winnipeg, Manitoba, Canada
www.imris.com
763.203.6300
Sales Inquiries, 763.203.6308;
Press Inquiries, Kevin Berger
kberger@imris.com
763.203.6332
IMRIS offers multiple product lines for image guided
neurosurgery solutions.
Monteris Medical, Inc.
Plymouth, MN; Winnipeg, Manitoba, Canada
www.monteris.com
info@monteris.com
763.253.4710
Monteris Medical produces medical devices for
MRI-guided neurosurgical ablation.
Summit Medical, Inc.
(Parent Corporation: Shore Capital Partners, LLC)
St. Paul, MN
www.summitmedicalusa.com
customerservice@summitmedicalusa.com
651.789.3939
Summit Medical offers expertise in medical device
development for neurosurgery applications.
Finance
Bay City Capital LLC
San Francisco, CA
www.baycitycapital.com
415.676.3830
Bay City Capital is a life sciences investment firm
with a global diversified strategy ranging from seed
stage to public companies, and including innovation,
restructuring opportunities, and growth investing.
Brain Trust Accelerator Fund, L.P.
Burlingame, CA
www.braintrustvc.com
650.375.0200
John M. Reher, Managing Director
Brain Trust Accelerator Fund focuses on early stage
investments that address the diagnosis and
treatment of brain-related diseases.
Craig-Hallum Capital Group LLC
Minneapolis, MN
www.craig-hallum.com
612.334.6300
Craig-Hallum Capital Group is an institutional
investment banking firm with expertise in health
technology and medical devices.
Gopher Angels, LLC
Minneapolis, MN
www.gopherangels.com
763.231.9676
David Russick, Managing Director
david.russick@russickgroup.com
Gopher Angels is a network of accredited investors
seeking to invest capital and expertise in early stage
Minnesota businesses. The organization is a member
of the Angel Capital Association.
Greatbatch, Inc.
Frisco, TX
www.greatbatch.com
214.618.4982
Betsy Cowell, VP Finance and Treasurer
ecowell@greatbatch.com
Greatbatch actively invests in targeted technology
and acquisitions to drive expansion in core and
adjacent markets.
17

19. Neuro Device Innovations (NDI) Medical, LLC
Minneapolis, MN
www.ndimedical.com
info@ndimedical.com
612.770.0390
Neuro Device Innovations (NDI) Medical is a hybrid
venture capital and commercialization firm
focusing exclusively on innovative neurodevice
technologies that are intended to restore lost
neurological function, prevent damage, and reduce
the painful effects of disease and injury.
NeuroVentures Capital LLC
Charlottesville, VA
www.neuroventures.com
info@neuroventures.com
434.297.1000
NeuroVentures Capital is a specialty venture capital
firm dedicated to investing in companies focused
on discovery, development, and marketing of new
therapeutics and technologies to treat Central
Nervous System disorders.
Oak Investment Partners
Minneapolis, MN
www.oakinv.com
612.339.9322
Oak Investment Partners is a private equity firm
focusing on venture capital investments in
companies developing systems and services in
healthcare and other industries.
Piper Jaffray Companies
Minneapolis, MN
www.piperjaffray.com
612.303.6000
Piper Jaffray is a well-established investment
banking firm with expertise in health technology and
medical devices.
RAIN Source Capital
St. Paul, MN
www.rainsourcecapital.com
651.632.2140
RAIN Source Capital organizes community-based
networks of investors, capital, and expertise to
benefit private investors, private companies, and
communities through leadership and ROI.
Shore Capital Partners, LLC
Chicago, IL
www.shorecp.com
info@shorecp.com
312.348.7580
Shore Capital Partners is a healthcare-focused lower
middle market private equity firm that specializes
in partnering with companies that have between $5
and $50 million of revenue.
Smiths Group plc
London, England
www.smiths.com
T.+44 (0) 20.7808.5512
Peter Durman, Director, Investor Relations &
Corporate Communications
investor.relations@smiths.com
Smiths Group buys businesses that add
complementary technologies and products, expand
geographical footprint in emerging markets, or
leverage existing infrastructure to increase
shareholder returns.
Technology Partners
Palo Alto, CA
www.technologypartners.com
admin@technologypartners.com
650.289.9001
Technology Partners builds and invests in venture
companies at all stages with a focus on life science
and clean technologies.
Third Rock Ventures, LLC
Boston, MA; San Francisco, CA
www.thirdrockventures.com
617.585.2000
Third Rock Ventures is a bi-coastal, multi-
disciplinary team that brings together the best of
science, strategy, business, and medicine.
Thomas McNerney & Partners, LLC
Minneapolis, MN
www.tm-partners.com
612.465.8660
Thomas McNerney & Partners is a healthcare venture
firm that invests in life science and medical
technology companies at all stages of development.
Twin Cities Angels
Minneapolis, MN
www.twincitiesangels.com
Twin Cities Angels provides a formal organization
for entrepreneurially-minded angel investors. Their
expertise is in medical devices, diagnostics, pharma,
and biotech.
Versant Ventures
San Francisco, CA
www.versantventures.com
415.801.8100
Versant Ventures is a leading healthcare investment
firm that invests across the healthcare sector with
an emphasis on the discovery and development of
novel therapeutics.
18

20. Intellectual Property -
Medical Devices
Beck & Tysver PLLC
Minneapolis, MN
www.becktysver.com
612.915.9633
Beck & Tysver is an innovative Minneapolis patent
law firm with experienced attorneys specializing in
software technology and medical devices.
BitLaw Legal Resource
Online Directory
www.bitlaw.com/links/firms.html
BitLaw Legal Resource is a free legal resource
focused on intellectual property; the service also
curates a list of IP Law Firms in MN.
Mayo Clinic Ventures
Rochester, MN
ventures.mayoclinic.org
mayoclinicventures@mayo.edu
507.293.3900
Kelly Krajnik, krajnik.kelly@mayo.edu;
Andy Danielsen, danielsen.andrew@mayo.edu
Mayo Clinic Ventures works closely with Mayo Clinic
physicians and scientists to mine inventions, ideas,
and discoveries that will truly transform healthcare.
Mueting, Raasch & Gebhardt, P.A.
Minneapolis, MN
www.mrgs.com
612.305.1220
Mueting, Raasch & Gebhardt provides expertise in
all areas of patent law relating to the electrical and
mechanical arts.
Patterson Thuente Pedersen, P.A.
Minneapolis, MN
www.ptslaw.com
info@ptslaw.com
612.349.5740
Patterson Thuente Pedersen excels at finding
strategic solutions to complex intellectual property
matters, with special expertise in technology IP.
The General Counsel, Ltd.
Minneapolis, MN
www.gcl.com
612.670.7687
Jonathan Eisenberg, Principal Attorney
jon.eisenberg@gcl.com
612.801.5659
The General Counsel offers companies the
advantages of experienced in-house legal counsel
on an affordable, outsourced basis.
Other - Supporting Infrastructure
BioAM
Rochester, MN
www.bioam.org
bioamroch@gmail.com
507.993.1918
BioAM is committed to engaging with local
entrepreneurs and connecting them with people and
resources their venture needs to be successful.
CoCo-MSP (Google for Entrepreneurs)
Multiple locations
www.cocomsp.com
hello@cocomsp.com
612.545.5745
CoCo-MSP is one of nine North American tech hubs
in the Google for Entrepreneurs network providing
space, funding, and mentorship to help launch
innovative companies.
Destination Medical Center
Rochester, MN
www.dmc.mn
Destination Medical Center (DMC) is an innovative
economic development initiative to secure
Minnesota’s status as a global medical destination
now and in the future.
LifeScience Alley
St. Louis Park, MN
www.lifesciencealley.org
952.542.3077
LifeScience Alley is a trade association working to
enable business success in the life science and health
technology industries by providing leadership,
advocacy, business referrals, and access to
intelligence and information.
Mayo Clinic Business Accelerator
Rochester, MN
www.mcbusaccel.com
507.288.0208
Xavier Frigola
xfrigola@raedi.com
Mayo Clinic Business Accelerator provides
infrastructure that enables entrepreneurism for
the Rochester community.
Rochester Business Alliance
Rochester, NY
www.rochesterbusinessalliance.com
585.244.1800
19

21. Startup Venture Loft (SVL)
Minneapolis, MN
www.svl.co
612.926.3878
Pete Kane
612.926.3878
Startup Venture Loft (SVL) is building a better
entrepreneurial ecosystem by providing Minnesota
startups with space, connections, and the resources
they need to be successful.
Treehouse Health
Minneapolis, MN
www.treehouse-health.com
612.486.5932
TreeHouse Health is a healthcare innovation center
with an emphasis on health IT and care coordination;
it provides expertise, investment, space, networks,
and professional services.
University Enterprise Laboratories
St. Paul, MN
www.uelmn.org
651.641.2800
Greg LaSalle
glasalle@uelmn.org
651.641.2803
University Enterprise Laboratories (UEL) is a
collaborative research center for early stage
bioscience ventures. They provide premier facilities
and services that enable innovation, growth, and
commercial success.
University of Minnesota - Business
Accelerator Program
Minneapolis, MN
diversity.umn.edu/bced/businessacceleratorprogram
612.624.3578
Mauvalyn Bowen, PhD
bowen075@umn.edu
The University of Minnesota’s Business Accelerator
Program is a dynamic business mentorship-based
program designed to accelerate growth of early
stage, high-potential small businesses located in the
Twin Cities.
University of Minnesota - MN-IP: Minnesota
Innovation Partnerships
Minneapolis, MN
www.research.umn.edu/mn-ip
612.625.3394
The University of Minnesota’s Minnesota Innovation
Partnerships (MN-IP) is designed to improve access to
university-developed technology while reducing the
risk and cost associated with licensing intellectual
property and sponsoring research.
University of Minnesota - Office for Technology
Commercialization (OTC)
Minneapolis, MN
www.research.umn.edu/techcomm
612.624.0550
The University of Minnesota’s Office for Technology
Commercialization (OTC) facilitates the transfer of
university research to licensees for the development
of new products and services that benefit the public
good, foster economic growth, and generate revenue
to support the University’s research and education
goals.
20

22. Clinical Expertise
Ablation
Samuel J. Asirvatham, MD – Neurovascular & PNS
Mayo Clinic, Department of Anesthesiology &
Pain Medicine
200 First St. SW
Rochester, MN 55905
507.284.2511
Depression
Barry Rittburg, MD – DBS, VNS, TMS
University of Minnesota, Department of Psychiatry
rittb001@umn.edu
612.273.9813
Epilepsy
Jamie J. Van Gompel, MD – DBS
Mayo Clinic, Department of Neurosurgery
& Otorhinolaryngology
200 First St. SW
Rochester, MN 55905
507.284.8008
Kendall H. Lee, MD, PhD - DBS
Mayo Clinic, Department of Neurosurgery
200 First St. SW
Rochester, MN 55905
Lee.Kendall@mayo.edu
507.284.8008
Squire (Matt) M. Stead, MD, PhD – DBS
Mayo Clinic, Department of Neurosurgery
200 First St. SW
Rochester, MN 55905
507.284.7341
Movement Disorders
David Rottenberg, MSc, MD - DBS
University of Minnesota, Department of Neurology
rotte001@umn.edu
612.467.4784
Anthony Santiago, MD – DBS
University of Minnesota, Department of Neurology
asantiag@umn.edu
612.301.1048
Jerrold Vitek, MD – DBS
University of Minnesota, Department of Neurology
vitek004@umn.edu
612.624.1903
Michael C. Park, MD - DBS
University of Minnesota, Department of Neurosurgery
200 First St. SW
Rochester, MN 55905
mcpark@umn.edu
612.626.4706
Anhar Hassan, MB, BCh – DBS
Mayo Clinic Department of Neurology
hassan.anhar@mayo.edu
507.284.2511
Kendall H. Lee, MD, PhD - DBS
Mayo Clinic, Department of Neurosurgery
200 First St. SW
Rochester, MN 55905
lee.kendall@mayo.edu
507.284.8008
Julie A. Fields, PhD, LP – DBS
Mayo Clinic, Department of Psychiatry
and Psychology
fields.julie@mayo.edu
507.284.2511
Squire (Matt) M. Stead, MD, PhD - DBS
Mayo Clinic, Department of Neurosurgery
200 First St. SW
Rochester, MN 55905
507.284.7341
Bryan T. Klassen, MD - DBS
Mayo Clinic Department of Neurology
klassen.bryan@mayo.edu
507.284.2511
Dr. Matthew D. Johnson – DBS (pre-clinical)
University of Minnesota, Department of
Biomedical Engineering
6-134 Hasselmo Hall
312 Church St SE
Minneapolis, MN 55455
john5101@umn.edu
612.626.6492
APPENDIX 2:
CLINICAL, SURGICAL, RESEARCH
& BUSINESS RESOURCES
Author’s note: List is not exhaustive and will be updated as needed.
21

23. Obesity
Charles Billington, MD – VNS
University of Minnesota, Department of Medicine
billi005@umn.edu
612.725.2000 x4423
Pain
Paul Gigante, MD - SCS
Spine and Brain Clinic
6545 France Ave. S., Ste 450D
Edina, MN 55435
952.836.3695
Michael C. Park, MD - DBS
University of Minnesota, Department of Neurosurgery
200 First St. SW
Rochester, MN 55905
mcpark@umn.edu
612.626.4706
Tim J. Lamer, MD – SCS, PNS, CNS-targeted
Drug Delivery
Mayo Clinic, Department of Anesthesiology
& Pain Medicine
200 First St. SW
Rochester, MN 55905
507.284.2511
Halena M. Gazelka, MD – SCS, PNS, CNS-targeted
Drug Delivery
Mayo Clinic, Department of Anesthesiology
& Pain Medicine
200 First St. SW
Rochester, MN 55905
507.284.2511
Jason S. Eldridge, MD – SCS, PNS, CNS-targeted
Drug Delivery
Mayo Clinic, Department of Anesthesiology
& Pain Medicine
200 First St. SW
Rochester, MN 55905
507.284.2511
Brenton M. Meier, MD – SCS, PNS, CNS-targeted
Drug Delivery
Mayo Clinic, Department of Anesthesiology
& Pain Medicine
200 First St. SW
Rochester, MN 55905
507.284.2511
Psychiatric Disorders
Barry Rittburg, MD – DBS, VNS, TMS
University of Minnesota, Department of Psychiatry
rittb001@umn.edu
612.273.9813
Kendall H. Lee, MD, PhD - DBS
Mayo Clinic, Department of Neurosurgery
200 First St. SW
Rochester, MN 55905
Lee.Kendall@mayo.edu
507.284.8008
Susannah J. Tye, PhD – DBS
Mayo Clinic, Department of Neurosurgery
200 First St. SW
Rochester, MN 55905
507.284.8008
Stroke
James R. Carey, PhD, PT, FAPTA – TMS, fMRI
University of Minnesota, Program in Physical Therapy
377 Children’s Rehab Center
carey007@umn.edu
612.626.2746
Teresa Jacobson Kimberley, PhD, PT - TMS, fMRI
University of Minnesota, Brain Plasticity Laboratory
tjk@umn.edu
612.626.4096
Bernadette Gillick, PhD, MS, PT – TMS, fMRI
University of Minnesota, Brain Plasticity Laboratory
gillick@umn.edu
612.626.3121
Wynn Legon, PhD - TMS, tACS/tDCS, and Ultrasound
Stimulation, fMRI
University of Minnesota, Brain Plasticity Laboratory
wlegon@umn.edu
612.626.1183
Bin He, PhD – TMS, tDCS
University of Minnesota, Department of Biomedical
Engineering, Center for Neuroengineering
6-124 Nils Hasselmo Hall
binhe@umn.edu
612.626.1115
Surgical Expertise
Mayo Clinic, Department of Neurosurgery
200 First St. SW
Rochester, MN 55905
507.284.8008
Fairview Hospital, Spine and Brain Clinic
6545 France Ave. S., Ste 450D
Edina, MN 55435
952.836.3695
22

24. Surgical Expertise (Cont’d)
University of Minnesota, Experimental
Surgical Services
Medical Center Department of Surgery
Stefanie B. Yorek, contact for appointment
scheduling
yorek001@umn.edu
612.625.4937
University of Minnesota, Division of Gastrointestinal
& Bariatric Surgery
Medical Center Department of Surgery
612.625.8446
University of Minnesota, Movement Disorders
& Epilepsy Surgery Center
Medical Center Department of Surgery
612.626.6688
University of Minnesota, Neurosurgery Clinic
Medical Center Department of Surgery
612.624.6666
University of Minnesota, Center for Minimally
Invasive Surgery
Medical Center Department of Surgery
612.672.7422
Clinical Centers
Mayo Clinic, Traumatic Brain Injury Program
200 First St. SW
Rochester, MN 55905
Nicole L. Dernbach
TBIMS@mayo.edu
507.255.0718
VA Office of Research & Development- Polytrauma/
Blast-Related Injuries - Quality Enhancement
Research Initiative
Princess Osei-Bonsu, PhD, MSPH - PBRI
Implementation Research Coordinator
princess.osei-bonsu@va.gov
612.467.7726
Mayo Clinic, Alzheimer’s Disease Research Center
200 First St. SW
Rochester, MN 55905
mayoadc@mayo.edu
507.284.1324
Mayo Clinic, Diabetes Center
200 First Street SW
Rochester, MN 55905
John Miles, MD
miles.john@mayo.edu
507.255.0001
Mayo Clinic, Migraine Research Program
Mayo Building, West Eighth Floor
200 First St. SW
Rochester, MN 55905
migrainersearchprogram@mayo.edu
507.266.7180
Minnesota Obesity Center
St. Paul, MN 55108
Dr. Catherine C. Welch, Program Coordinator
mnoc@tc.umn.edu
763.807.0559
University of Minnesota, Brain Plasticity Laboratory
306 Children’s Rehabilitation Center
426 Church Street SE
Minneapolis, MN 55455
612.626.4096
Mayo Clinic, CT Clinical Trials Innovation Center
200 First St. SW, Rochester, MN 55905
CTCIC@mayo.edu
507.538.7723
University of Minnesota, The Memory Clinic
The N. Bud Grossman Center for Memory Research
and Care
5775 Wayzata Blvd in Suite #200,
Minneapolis, MN 55416
memclin@umn.edu
Clinic Appointments: 952.525.4500
Imaging Centers
University of Minnesota, Center for Magnetic
Resonance Research
2021 Sixth Street SE, Minneapolis, MN 55455
Deb Morgan, Executive Assistant
deb@cmrr.umn.edu
612.626.2001
University of Minnesota, Center for Clinical
Imaging Research
2021 Sixth Street SE, Minneapolis, MN 55455
ccir@umn.edu
612.626.6900
Mayo Clinic, Center for Advanced Imaging Research
200 First Street SW
Rochester, MN 55905
Stephen J. Riederer, PhD
riederer@mayo.edu
507.284.6209
University of Minnesota, Biomedical Functional
Imaging and Neuroengineering Laboratory
7-105 Hasselmo Hall, 312 Church St. SE,
Minneapolis, MN 55455
612.626.1114
23

25. Research Centers
Mayo Clinic, Center for Clinical and Translational
Science (CCaTS)
200 First Street SW
Rochester, MN 55905
507.255.7101
University of Minnesota, Clinical and Translational
Science Institute
717 Delaware Street SE, Second Floor
Minneapolis, MN 55414
ctsi@umn.edu
612.625.CTSI (2874)
Mayo Clinic, Department of Defense Medical
Research Office
Strategic Funding Office for Research
200 First St. SW
Rochester, MN 55905
Jon W. Zurn
strategicfunding@mayo.edu
507.266.4554
Mayo Clinic, Evidence-Based Practice
Research Program
Harwick Building, Room 2-54
Rochester, MN 55905
507.266.1829
Fairview Research Administration
2344 Energy Park Drive
Saint Paul, MN 55108
research@fairview.org
612.672.7690
Research Helpline: 612.672.7692
University of Minnesota, Neuromodulation Research
and Technology Laboratory
6-134 Hasselmo Hall
312 Church St SE
Minneapolis, MN 55455
Dr. Matthew D. Johnson
john5101@umn.edu
612.626.6492
University of Minnesota, Institute for Engineering
in Medicine
420 Delaware Street Southeast
725 Mayo Memorial Building, MMC 609
Minneapolis, MN 55455
iem@umn.edu
612.626.5493
University of Minnesota, Center for Neuroengineering
1-205 NHH, 312 Church Street, SE
Minneapolis, MN 55455
cne@umn.edu
612.625.7209
University of Minnesota, Center for Design in Health
1425 University Ave SE
Minneapolis, MN 55414
Kathleen A. Harder, PhD, Director
kharder@umn.edu
612.626.0026
University of Minnesota, Brain Sciences Center
Minneapolis Veterans Affairs Medical Center
One Veterans Drive
Minneapolis, MN 55417
Amy Wicklund, Administrator
bsc@umn.edu
University of Minnesota, Institute for
Translational Neuroscience
2101 6th Street SE
Minneapolis, MN 55455
Rosalyn Segal, Administrative Director
rsegal@umn.edu
612.625.6966
University of Minnesota, National Institute of
Neurodegenerative Disorders & Stroke Center
Tim Ebner, PhD, Co-Director
ebner001@umn.edu
612.626.6800
Harry Orr, PhD, Co-Director
orrxx002@umn.edu
612.625.3647
University of Minnesota, Office of the Vice President
for Research
101 Pleasant Street
Minneapolis, MN 55455
612.625.3394
MnDRIVE – Brain Conditions Initiative
University of Minnesota, Office of the Vice President
for Research
Tim Ebner, PhD, Research Lead
ebner001@umn.edu
612.626.6800
University of Minnesota, Medical Devices Center
(MDC)
Greg Peterson, Innovation Collaborator
Office Location: G217-08 Mayo Building
gkpeters@umn.edu
612.626.4615
24

26. Additional Resources (MN/US/Global)
Policy, Education & Advocacy
LifeScience Alley
1550 Utica Ave So, Suite 725,
St. Louis Park, MN 55416
connect@lifesciencealley.org
952.542.3077
Medical Device Innovation Consortium (MDIC)
1550 Utica Ave So, Suite 740
St. Louis Park, MN 55416
952.314.1255
Minnesota High Tech Association (MHTA)
400 South 4th Street, Suite 416
Minneapolis, MN 55415
952.230.4555
Neurotechnology Industry Organization (NIO)
Works to accelerate neurotechnology research,
development and commercialization, including
neuroscience companies, brain research institutes,
and patient advocacy groups.
North American Neuromodulation Society (NANS)
Promotes multidisciplinary collaboration among
clinicians, scientists, engineers, and others to
advance neuromodulation through education,
research, innovation and advocacy.
The International Neuromodulation Society (INS)
Nonprofit group of clinicians, scientists and
engineers dedicated to the scientific development
and awareness of neuromodulation.
Market Reports
NeuroInsights
Provides neurotech industry newsletters,
comprehensive market reports, neurotech
investment conferences and strategic advisory
services.
Neurotech Reports
Offers up-to-date and forward-looking information
about the field of neurotechnology and future
developments that will affect the venture capital,
research, and start-up communities.
25

27. ®
Leading the conversation.
LifeScience Alley’s intelligence and research work
is generously supported by our Foundational Members.
3M | Boston Scientific | Mayo Clinic | Medtronic | St. Jude Medical